So, Pappy, CVM is "Starting" to use Automated Trading Programs? Who knew...
HO HO, WOW... Another 100 share trade...
Sentiment... Maybe the MM's are with geertie in the Islands planning the next sheep shearing...?
I remember when Geert stated, in an interview, the trial would be completed in April and that was 4 months late. Once again a date was missed...With the 118 added the trial will be completed late Q4.
You well know arbittration has been moved to September. Quit acting. And you are not a lawyer..GEEEEZE!
Dream on .....$250m? More like $35m out of court. Remember the last court suit Geert won? It COST the company 12m, lol.
For those of you with long memories, in 2010 inVentiv Health (a clinical research organization -CRO- that is being sued by CVM for negligence and fraud) was taken private by senior mgt. Now, 6 years later they are going to issue enough shares to take the company public again. The arbitrated lawsuit with CVM is scheduled for a final hearing this month. Per Geert Kersten, the evidence they have is so compelling that a legal firm gave Cel-Sci $5M for a percentage of what is recovered, plus the $5M. In addition, the CRO that CVM is now using to conduct the phase III trial has enrolled over 724 patients world-wide. The results must be good because the CRO put $12M into the company to increase their royalty share. They wouldn't do this if they didn't have the first-hand results they have of the on-going trials. Geert said on Fox News, in an interview, that he himself bought an additional 3M shares of CVM stock in February. My guess, and it is just a guess, that inVentiv which is seeking to raise $500M in their initial public offering (they HAVE HIRED Morgan Stanley and Credit Suisse to co-lead the offering), will settle the legal battle with CVM for $200M to $250M. The rest will be used by inVentiv for investment/growth purposes.
Finally, on Feb 15 Cel-Sci sold 1.3M shares plus 650K warrants to an unnamed organization (could be the CRO they now work with) for $0.48/share (which is what the stock was trading at -- here is the link: https://biz.yahoo.com/e/160217/cvm8-k.html).
Given that with CVM at $0.62/share and with 130M shares outstanding, the whole company is worth about $80M. With a settlement of $250M that should send CVM shares to over $2/share. Add to this positive comments by Geert and CVM could easily become a $10 stock.
Two links, different interviews, with Geert on the Phase III: https://www.youtube.com/watch?v=lQ8DnD6Uz3E
Something interesting under "risks" from page 11:
Our insurance may not cover all of our indemnification obligations and other liabilities associated with our operations.
We maintain insurance designed to provide coverage for ordinary risks associated with our operations and our ordinary indemnification obligations. The coverage provided by such insurance may not be adequate for all claims we may make or may be contested by our insurance carriers. If our insurance is not adequate or available to pay liabilities associated with our operations, or if we are unable to purchase adequate insurance at reasonable rates in the future, our profitability may be adversely impacted.
cold fill = $$$
LEAPS = $$$
H1N1 = $$$$$$ (BEST "Suckers paly")
Oh, I'm sorry, here I go again thinking that shareholders (traders) made $$$, when it was only Geert & Max...My bad :(
We are almost there. Based on the excellent results of the Phase II trial, I don't think there can be any doubt that as the final slots are filled in the Phase III trial, this price is going to continue to rise just like it has been the last few months.
Also, watch how fast the few negative guys try and push this post down the board. It's funny to watch how just a very few shorters with anxious fingers can monopolize a board.
April 27th, 2016 • 0 comments • Filed Under • by ABMN Staff
CEL-SCI Co. (NYSE:CVM) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 4,582,291 shares, a drop of 4.6% from the March 31st total of 4,804,903 shares, Market Beat reports. Approximately 4.1% of the shares of the company are sold short. Based on an average trading volume of 296,281 shares, the short-interest ratio is currently 15.5 days.
Separately, Zacks Investment Research downgraded shares of CEL-SCI from a “buy” rating to a “hold” rating in a research report on Tuesday, February 16th.
Shares of CEL-SCI (NYSE:CVM) opened at 0.5636 on Wednesday. CEL-SCI has a 12 month low of $0.36 and a 12 month high of $1.03. The company’s market capitalization is $75.07 million. The stock’s 50 day moving average is $0.56 and its 200 day moving average is $0.51.
.... Watch and learn ...!
Sentiment... Luv this ATM.... Hate geertie and maxhole..!
P.S... Pump it yankeepoo, pump it...!
Anyone who takes Geert's comments at face value and acts accordingly loses everything.
I doubt very much that if PharmaNet employees were distracted and its business thus disruopted, as CVM claims, that only this wretched POS CVM's trial was harmed.
It's another sucker's play, along with cold fill, LEAPS H1N1, etc.